Table 3

TGF-β1 T+29C and C-509T polymorphisms in association with overall survival and disease-free survival, Shanghai Breast Cancer Study

HRa (95%)HRb (95%)
T+29C
 Overall survival
  TT1.01.0
  TC1.4 (0.9–2.0)1.2 (0.8–1.8)
  CC1.2 (0.8–1.9)1.1 (0.7–1.6)
  TC/CC1.3 (0.9–1.9)1.1 (0.8–1.7)
 Disease-free survival
  TT1.01.0
  TC1.6 (1.1–2.2)1.4 (1.0–2.1)
  CC1.5 (1.0–2.2)1.3 (0.9–1.9)
  TC/CC1.5 (1.1–2.2)1.4 (1.0–1.9)
C-509T
 Overall survival
  CC1.01.0
  TC1.3 (0.9–1.9)1.1 (0.8–1.7)
  TT1.3 (0.8–1.9)1.0 (0.7–1.6)
  TC/TT1.3 (0.9–1.9)1.1 (0.7–1.6)
 Disease-free survival
  CC1.01.0
  TC1.5 (1.1–2.2)1.4 (0.9–2.0)
  TT1.5 (1.0–2.2)1.3 (0.8–1.9)
  TC/TT1.5 (1.1–2.1)1.3 (0.9–1.9)
  • a HR, hazard ratio adjusted for age (<42, 42–46, 47–52, 53–64).

  • b Adjusted for age (<42, 42–46, 47–52, 53–64), education (<middle school, middle school, >middle school), tumor-node-metastasis (0–I, II, III, IV, unknown), radiotherapy (yes, no, unknown), chemotherapy (yes, no, unknown), estrogen receptor status (positive, negative, unknown), progesterone receptor status (positive, negative, unknown), and tamoxifen use (yes, no, unknown).